Sweeping doubts aside, Eli Lilly beats Regeneron to emergency OK — clearing low dose antibody for quick rollout
Eli Lilly has clinched the first emergency use authorization issued for an antibody against Covid-19, setting in motion a $1.2 billion deal to supply …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.